Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07718165 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Sep 1, 2026 to Aug 28, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Sep 1, 2026 to Aug 28, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.
Trial Details
NCT Number NCT07718165
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions Solid Tumor (Phase I)
Enrollment 247 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov